Noble Capital Markets Initiates Research Coverage on ESSA Pharma Inc. (EPIX)

NEW YORK, Feb. 17, 2017 /PRNewswire

Noble Capital Markets announced today that it has initiated research coverage on ESSA Pharma Inc. (EPIX). The report was issued by Noble's Head of Biotechnology Research, Kumar Raja, PhD.

ESSA Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments for castration resistant prostate cancer (CRPC). Its lead compound EPI-506, is a small molecule oral drug that selectively blocks the amino-terminal domain of the androgen receptor, thereby has potential to overcome some of the known androgen receptor dependent resistance mechanisms of CRPC. EPI-506 is in Phase 1/2 trial for the treatment of castration-resistant prostate cancer and based on it differentiated mechanism of action could potentially lead to increased progression-free and overall survival compared to the drugs approved for treatment of CRPC. The full report and disclosures can be accessed by clicking here.

For further information please contact Steve Rashkin at 561-994-5738

About Noble Capital Markets
Noble Capital Markets established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton (HQ), New York and Boston. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous "non-deal" corporate road shows and sector-specific conferences such as the Media, Finance & Investor Conference offered in partnership with the National Association of Broadcasters (NAB).


This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results.

Please see disclosure, valuation methods, price charts, and ratings histories available in the complete research report, available by clicking here or contacting Noble Capital Markets at 561-994-5738. The securities covered by or mentioned in the reports involve substantial risk and should generally be purchased only by investors able to accept such risk.

Noble Capital Markets is a member of the Financial Industry Regulatory Authority, CRD number 15768.

To view the original version on PR Newswire, visit: